[Use of the peptide hormone melanostatin and its analogs for the synthesis of new antitumor compounds]. 1988

N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova

A hypothalamic hormone--melanostatin H-L-Pro-L-Leu-NH2- and its 9 analogs were synthesized and their antitumor properties studied. Melanostatin caused a 52-72% inhibition of tumor growth (p less than 0.05) in mice bearing adenocarcinoma of the mammary gland Ca-755, cervical carcinoma CC-5 and melanoma B-16. Non-cytotoxic analogs containing D-leucine or L-lysine showed low activity. Among analogs containing sarcolysine stereomers, chlorphenacyl or chlorambucil, derivatives with L-sarcolysin exerted a high antitumor effect on Ca-755, CC-5, Lewis lung carcinoma, lymphoid leukemia L-1210, sarcoma-37, melanoma B-16 and S-91 (80-99% inhibition of tumor growth, p less than 0.05). L-sarcolysin alone had a higher effect on S-91 only (p less than 0.05). Antitumor effect of melanostatin is due to its amino acid sequences. Melanostatin analogs modified by L-phenylalanine retain their antitumor properties.

UI MeSH Term Description Entries
D008297 Male Males
D009075 MSH Release-Inhibiting Hormone A hypothalamic tripeptide, enzymatic degradation product of OXYTOCIN, that inhibits the release of MELANOCYTE-STIMULATING HORMONES. MSH Release-Inhibiting Factor,Melanocyte-Stimulating Hormone Release-Inhibiting Hormone,Prolyl-Leucyl-Glycinamide,H-Pro-Leu-Gly-NH2,MIF-1,MIF-I,Melanocyte-Stimulating Hormone Release-Inhibiting Factor,Melanostatin,Oxytocin (7-9),Pro-Leu-Gly-NH2,Pro-Leu-Glyamide,Prol-Leu-Gly-NH2,Prolylleucylglycinamide,Prol Leu Gly NH2,Prolyl Leucyl Glycinamide
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
January 1991, The Journal of antibiotics,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
December 1999, Trends in endocrinology and metabolism: TEM,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
December 2016, Marine drugs,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
July 2012, European journal of medicinal chemistry,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
December 1990, Bioorganicheskaia khimiia,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
April 2009, Bioorganic & medicinal chemistry letters,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
October 1997, Journal of medicinal chemistry,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
January 1976, Acta poloniae pharmaceutica,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
May 2018, European journal of medicinal chemistry,
N D Lagova, and Z S Smirnova, and Z P Sof'ina, and L I Smirnova, and N M Kashnikova
September 2017, European journal of medicinal chemistry,
Copied contents to your clipboard!